At Akums Drugs & Pharmaceuticals, our diversified business model spans across core pharmaceutical segments, emerging wellness categories, and global healthcare markets. Our integrated capabilities—ranging from contract development and manufacturing to branded marketing and API production—make us a comprehensive healthcare partner, empowering brands and businesses across the globe.
Contract manufacturing of pharmaceutical formulations remains the flagship business of Akums and contributes to over three-fourths of our total revenue. As India's leading CDMO, we are the trusted partner of more than 1,500 pharmaceutical companies. Akums has successfully commercialized over 4100+ formulations across 60+ dosage forms. Our CDMO business operates through 12 state-of-the-art manufacturing plants with a total installed capacity of 49+ billion units annually
Recognizing the surging demand in the wellness and preventive health sectors, Akums has made focused investments in nutraceutical and cosmeceutical manufacturing. We operate a dedicated subsidiary, Maxcure Nutravedics Ltd., which specializes in the development and manufacturing of nutraceuticals, herbal, and AYUSH-based products. For cosmeceuticals, we have a dedicated manufacturing block that caters to varied product delivery formats.
Akums has established its own presence in both the domestic branded formulation markets through Akumentis. Akumentis focuses on key therapeutic areas including gynaecology, cardiology, orthopaedics, and paediatrics in the Indian market, supported by a strong field force of over 1,500 professionals and a distribution network that spans pan-India. Unosource represents our branded presence across global markets. Together, these companies market more than 200 brands and reflect our deep commitment to making quality healthcare accessible and reliable.
India ranks third globally in pharmaceutical production by volume, and Akums plays a vital role in this achievement. Through Unosource, our dedicated export division, we have built a robust global footprint across 65+ countries. We cater to diverse therapy areas including anti-infectives, analgesics, CNS, and gynaecology. Our export partners include well-established names such as Allegens (Vietnam), Caferma SAC (Peru), Pharma Apex (Myanmar), and Olainfarm (Latvia), showcasing our credibility and global acceptance.
Our API division, Akums Lifesciences, has emerged as a key growth lever. Following the acquisition of Parabolic Drugs Ltd., we have made significant investments in modernizing API manufacturing facilities to meet stringent global standards. Today, we cater to both regulated and semi-regulated markets through a well-curated portfolio supported by intensive R&D. India’s push for self-reliance through PLI schemes and the expanding demand for formulations further strengthen our API business outlook.
Our robust R&D ecosystem enables us to deliver innovative, high-quality, and scalable solutions focused on formulation development, API innovation, and global regulatory compliance. With four state-of-the-art R&D centers, our expert teams drive rapid, effective research across therapeutic categories—transforming ideas into commercially viable, stable products.
Located strategically across Haridwar, Mumbai, and Barwala (Haryana) to cater to domestic and international requirements.
A highly experienced team with deep expertise in formulation development, analytical chemistry, process optimization, and IP management.
Proven capabilities in developing sustained release, taste-masked, pediatric, effervescent, and fixed-dose combination products.
Complete support from concept to commercialization, including technology transfer, scale-up, and dossier preparation.
Akums operates 15 world-class manufacturing facilities, producing around 10% of the total medicines consumed in India. These facilities span oral solids, oral liquids, sterile injectables, topical applications, ayurvedic medicines, food supplements, and animal healthcare products. Our manufacturing strength lies not only in our scale but also in our flexibility to cater to diverse At Akums, sustainability is not a goal—it is a responsibility we uphold across every level of our operations. Rooted in our Environmental, Social, and Governance (ESG) pillars, we continuously work toward creating a safer, greener, and more inclusive future.
At Akums, sustainability is embedded in our business philosophy, guided by strong Environmental, Social, and Governance (ESG) principles. We are committed to responsible growth that positively impacts people, the planet, and the broader community. Environmentally, we have achieved a 7.3% reduction in energy consumption and a 7.2% drop in CO₂ emissions at our formulation plants. Around 32% of our energy now comes from biogenic sources, with continuous investment in solar and cleaner fuels. We’ve also reduced freshwater consumption by 8.1% through recycling and reuse initiatives.
On the social front, we focus on safety, well-being, and inclusivity. With over 30,000 safety training hours and a Zero Harm approach, we’ve built a culture of care. Our CSR activities include blood donation drives, health camps, skill development centres, and tree plantation drives, promoting holistic community upliftment.
Diversity and inclusion remain central, with women comprising 24.8% of our workforce and year-on-year improvement in DEI practices. POSH awareness and equal opportunity policies are implemented across all locations, ensuring a fair and respectful workplace for all.
From a governance perspective, we follow global standards with certifications like ISO 9001, 14001, 45001, and 50001. Our ESG data is independently assured, and our practices are rooted in transparency, ethics, and accountability.